Serum Institute of India announced on Monday that the World Health Organization (WHO) has granted approval to a malaria vaccine, marking a significant milestone as the world’s second vaccine of its kind receives global recognition.
The endorsement is grounded in pre-clinical and clinical trial results, demonstrating both safety and remarkable efficacy across various regions with diverse malaria transmission patterns. This achievement positions the R21/Matrix-M malaria vaccine, developed in collaboration between the University of Oxford and the Serum Institute of India (SII) with the utilization of Novavax’s adjuvant technology, as the second WHO-recommended vaccine for preventing malaria in children, as per SII’s official statement.
